CHF 30.00
In stock
BVT-0244-C100100 µgCHF 30.00
BVT-0244-M0011 mgCHF 50.00
BVT-0244-M0055 mgCHF 90.00
More Information
Product Details
Synonyms 17-(Allylamino)-17-desmethoxygeldanamycin; Tanespimycin; NSC 330507
Product Type Chemical


MW 585.7
CAS 75747-14-7
Source/Host Chemicals Semi-synthetic derivative from geldanamycin.
Purity Chemicals ≥98% (HPLC)
Appearance Red to dark red powder.
Solubility Soluble in DMSO (10 mg/ml) or methanol (10 mg/ml).
Identity Determined by 1H-NMR.
Declaration Manufactured by BioViotica.
Smiles [H]/C1=C([H])/[C@H](OC)[C@@H](OC(N)=O)\C(C)=C\[C@H](C)[C@H](O)[C@H](C[C@H](C)CC2=C(NCC=C)C(=O)C=C(NC(=O)\C(C)=C\1)C2=O)OC
Shipping and Handling
Shipping AMBIENT
Short Term Storage +4°C
Long Term Storage -20°C
Handling Advice Protect from light when in solution.
Use/Stability Stable for at least 1 year after receipt when stored at -20°C.
After reconstitution protect from light at -20°C.
MSDS Download PDF
Product Specification Sheet
Datasheet Download PDF
  • Potent, less toxic analog of geldanamycin (Prod. No. BVT-0196).
  • Inhibits the essential ATPase activity of HSP90.
  • Telomerase activity inhibitor.
  • Apoptosis inducer.
  • Antitumor compound.
Product References
  1. Inhibition of the oncogene product p185erbB-2 in vitro and in vivo by geldanamycin and dihydrogeldanamycin derivatives: R.C. Schnur, et al.; J. Med. Chem. 38, 3806 (1995)
  2. The benzoquinoneansamycin 17-allylamino-17-demethoxygeldanamycin binds to HSP90 and shares important biologic activities with geldanamycin: T.W. Schulte & L.M. Neckers; Cancer Chemother. Pharmacol. 42, 273 (1998)
  3. Gene expression profiling of human colon cancer cells following inhibition of signal transduction by 17-allylamino-17-demethoxygeldanamycin, an inhibitor of the hsp90 molecular chaperone: P.A. Clarke, et al.; Oncogene 19, 4125 (2000)
  4. Geldanamycin and its analogue 17-allylamino-17-demethoxygeldanamycin lowers Bcr-Abl levels and induces apoptosis and differentiation of Bcr-Abl-positive human leukemic blasts: R. Nimmanapalli, et al.; Cancer Res. 61, 1799 (2001)
  5. A high-affinity conformation of Hsp90 confers tumour selectivity on Hsp90 inhibitors: A. Kamal, et al.; Nature 425, 407 (2003)
  6. Geldanamycin and its 17-allylamino-17-demethoxy analogue antagonize the action of Cisplatin in human colon adenocarcinoma cells: differential caspase activation as a basis for interaction: I.A. Vasilevskaya, et al.; Cancer Res. 63, 3241 (2003)
  7. Inhibition of telomerase activity by geldanamycin and 17-allylamino, 17-demethoxygeldanamycin in human melanoma cells: R. Villa, et al.; Carcinogenesis 24, 851 (2003)
  8. Intratumor injection of the Hsp90 inhibitor 17AAG decreases tumor growth and induces apoptosis in a prostate cancer xenograft model: C.R. Williams, et al.; J. Urol. 178, 1528 (2007)
  9. Phase I and pharmacodynamic study of 17-(allylamino)-17-demethoxygeldanamycin in adult patients with refractory advanced cancers: R.K. Ramanathan, et al.; Clin. Cancer Res. 13, 1769 (2007)
  10. An in vitro and in vivo study of the combination of the heat shock protein inhibitor 17-allylamino-17-demethoxy- geldanamycin and carboplatin in human ovarian cancer models: U. Banerji, et al.; Cancer Chemother. Pharmacol. 62, 769 (2008)
  11. HSP90 inhibitor 17AAG causes apoptosis in ATRA-resistant acute pro-myelocytic leukemia cells: P.N. Meyer, et al.; Leuk. Res. 32, 143 (2008)
  12. Heat shock protein 90 inhibitors attenuate inflammatory responses in atherosclerosis: J. Madrigal-Matute, et al.; Cardiovascular Res. 86, 330 (2010)
© 2017 Adipogen Life Sciences. Pictures: © 2012 Martin Oeggerli. All Rights Reserved.